Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MRNA
MRNA logo

MRNA News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

MRNA News

The Importance of Market Capitalization for Investors

2d agoNASDAQ.COM

EMA Recommends Targeting XFG Variant for 2026/2027 Vaccines

2d agoseekingalpha

FDA Panel Recommends Updating COVID Vaccines for XFG Variant

2d agoseekingalpha

FDA Advisory Panel to Vote on COVID Vaccine Target Variant

3d agoNewsfilter

FDA Advisory Panel to Discuss 2026-2027 COVID Vaccine Composition

5d agoseekingalpha

Workday and Lumentum Options Trading Active

May 21 2026NASDAQ.COM

Moderna's Flu Vaccine Approval Faces New Setback

May 21 2026stocktwits

Moderna's Flu Vaccine Application Set for FDA Review

May 21 2026seekingalpha

MRNA Events

05/22 09:50
Exxon Mobil in Talks to Acquire Oil Production Rights in Venezuela
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.VENEZUELAN OIL:Exxon Mobilis in talks to acquire rights to produce oil in Venezuela nearly two decades after it was effectively expelled from the country, several people familiar with the matter told' Anatoly Kurmanaev. If finalized, the deal would mark Exxon's return to the country after years of legal battles and be "a major victory for President Trump," the report stated.FLU VACCINE:Moderna'sexperimental mRNA-based flu vaccine will be reviewed by an FDA advisory panel on June 18 ahead of an August 5 approval decision, signaling a possible return to greater transparency in the agency's review process after advisory hearings became less common during the second Trump administration, Bloomberg's Rachel Cohrs Zhang and Gerry Smith.CHINA TRIP:Executives from companies including Boeing, Apple, Nvidia, and Teslajoined President Trump's delegation to China seeking support from both governments while also pressing Beijing over business restrictions, including blocked solar equipment exports to Tesla, supply constraints affecting Coherent, and delays approving Nvidia's H200 chip sales in China, The New York Times' Ana Swanson. Following the summit, the U.S. and China announced limited progress including Chinese commitments to buy American agricultural products and 200 Boeing planes, while Citiappeared closer to securing approval for a wholly owned securities business in China, though many broader corporate concerns remain unresolved despite lobbying efforts coordinated with senior U.S. officials, Swanson writes.LOAN OFFER:The Pentagon is debating on scrapping an $80M conditional loan offer to ReElement Technologies, Joe Deaux and Kate O'Keeffe of Bloomberg reports. The Pentagon's Office of Strategic Capital announced the agreement with ReElement in November, but officials have since raised doubts about the company's ability to scale its technology, people familiar with the process told. The deal, which is meant to break China's chokehold on critical minerals, has not been canceled and may still go ahead, the sources added. Additionally, the deal is part of a bigger $1.4B critical-minerals agreement that includes Vulcan Elements and is part of the Trump admin's drive to develop domestic production of rare earth elements. Companies involved in the development and mining of rare earth minerals include Nova Minerals, Ioneer, Lynas Rare Earths, MP Materials, Energy Fuels, NioCorpand VanEck Vectors Rare Earth/Strategic Metals ETF.
05/21 11:20
Moderna's Flu Vaccine to be Reviewed by FDA on June 18
Moderna's experimental mRNA-based flu vaccine will be reviewed by an FDA advisory panel on June 18 ahead of an August 5 approval decision, signaling a possible return to greater transparency in the agency's review process after advisory hearings became less common during the second Trump administration, Bloomberg's Rachel Cohrs Zhang and Gerry Smith report.

MRNA Monitor News

Moderna's mRNA platform sets industry benchmark amid biotech growth

May 20 2026

Moderna's stock declines amid broader biotech market weakness

May 19 2026

Moderna's Stock Declines Despite Hantavirus Vaccine Research

May 13 2026

Moderna's Hantavirus Vaccine Research Sparks Investor Optimism

May 11 2026

Moderna Reports Strong Q1 2026 Earnings Driven by International Sales

May 08 2026

Moderna Reports Strong Q1 Earnings Driven by International Sales

May 06 2026

Moderna Reports Strong Q1 Earnings Driven by International Sales

May 04 2026

Moderna Reports Strong Q1 Earnings Amid Patent Lawsuit

May 01 2026

MRNA Earnings Analysis

Moderna Q3 2025 Earnings: Strategic Insights Unveiled- Intellectia AI™
6 months ago
Resilient Path Ahead - Intellectia AI™
1 years ago
Moderna Inc Reports Strong Financial Results for Third Quarter 2024
1 years ago

People Also Watch